On February 5, 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb Company. Breyanzi is a chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. [Read more…]
T Cells For Immune Defense: CAR-T Cell Therapies in 2025
Can T cells be an effective approach to cancer treatment? CAR T-cell therapy, as this cutting-edge treatment is called, uses a patient’s own immune system to help fight cancers in the body. The result is a natural treatment that proves effective against a variety of blood cancers and may have hope for other cancers in the future as well.
T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens.
Using T Cells For Cancer Treatment
In this article:
- CAR-T Cell Therapy Treatments for Treatment of Cancer
- What Causes Cancer?
- How Does the Immune System Work – and What Are Its Limits?
- What Is Immunotherapy?
- Are There Different Types of Immunotherapy?
- What Are T Cells?
- What Is CAR-T Cell Therapy?
- How Does CAR-T Cell Therapy Work?
- Who Is CAR-T Cell Therapy Right For?
- Why Doesn’t CAR-T Cell Therapy Work for Solid Tumors?
- Are There Any Risks?
- What Are the Benefits of CAR-T?
- How Effective Is CAR-T Treatment?
- Progress in CAR-T Cell Therapy Development
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
CHICAGO, IL, January 11, 2025 — VectorBuilder’s partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025. VectorBuilder has provided highly customized end-to-end CDMO solutions to support this clinical pipeline. [Read more…]
Stem Cell Treatments For Lungs? Paths to Relief and Recovery
Lung diseases can be debilitating, making both medical leaders and patients interested in exploring stem cell treatments for lungs. Find out what you need to know about stem cell therapy for lungs, including risks, benefits, clinical trial progress and more. [Read more…]
Innovative Functional Peptides Successfully Co-Developed as Alternatives to Growth Factors Used in the Manufacturing of Regenerative Medicine Products
Orizuru Therapeutics, Inc. (OZTx), a Japanese biotechnology company focusing on the research and development of iPSC-derived regenerative medicine, and PeptiGrowth Inc. (PeptiGrowth), a Japanese biotechnology company specializing in the development of synthetic peptide based growth factors, are pleased to announce the successful completion of the joint development project (first announced on August 23, 2023) for chemically synthesized peptide as an alternative to specific recombinant growth factors used in the manufacturing of regenerative medicine products developed by OZTx. The developed peptide was confirmed to bind to cellular receptors in a manner similar to the respective recombinant growth factor, inducing phosphorylation and signaling within the cells, thereby triggering differentiation and proliferation of iPSCs. [Read more…]
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 60
- Next Page »